Valerie Clark
Joined Patexia at Sep 29, 2011
Valerie Clark
Jun 1, 2012
It started with a basic soft drink cooler, a need for easier management of tuberculosis and $150,000 in innovation support.  A big challenge in managing tuberculosis is keeping the medicine cool, in addition to tracking and monitoring dose administration. These challenges can be life-threatening, especially in less-developed countries, where refrigerators... Read More
Valerie Clark
May 29, 2012
In a recent article published on the open e-print service arXiv, the role of biophotons in cell communication was analyzed by researchers looking for clues from fish eggs. The evidence suggests that biophotons function as cross-talk between cells, and the result is synchronization of cellular growth and development processes in... Read More
Valerie Clark
May 19, 2012
Mobile health apps are developing quickly, and they aim to replace and/or complement treatments prescribed by doctors. The newest app on the block is Happitique. This isn’t just an app; it’s an app for medical apps. Happitique has recently announced a mobile prescription (mRx) trial that will involve doctors, as... Read More
Valerie Clark
May 11, 2012
The most recent research coming out of the International Agency for Research on Cancer (IARC) reported that one in six cancers worldwide are caused by infections. This single finding created a big buzz in news headlines earlier this week; there were millions of reports containing headlines about cancers caused by... Read More
Valerie Clark
May 4, 2012
The buzz words of 2012 are officially “collaborative innovation.”  A 3-second Google search yields more than 3 million results containing these keywords. The basic idea is that many minds are better than one, especially when the demand for creativity and innovation is higher than ever before. By utilizing collaborative innovation,... Read More
Valerie Clark
Apr 27, 2012
International pharmaceutical giant Novartis is suing the United Kingdom's national health system (NHS) for using a cheaper, unlicensed drug instead of Novartis' licensed drug for treating age-related blindness. Even if Novartis wins the legal battle in the UK, and forces the NHS to use the $1,000 drug, it will (and... Read More